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Kouichi AKAHAN E, Kazuhisa FU R U HAMA, Fujiroh I NAG E and Takeshi ONODERA Drug Safety Research Center, Research Institute, Daiichi Seiyaku Co., Ltd., Edogawa-ku, Tokyo 134, Japan Accepted May 13, 1987 Abstract-Rats developed anemia during treatment with high doses of malotilate, a hepatotropic agent. A repeated dose of 1,000 mg/kg caused a 20-30% decrease Malotilate (diisopropyl 1,3-dithiol-2 ylidenemalonate) has a hepatotropic effect, in particular improving protein metabolism in the liver (1) . It causes marked improvements in reduced serum cholesterol and albumin levels and improves cholinesterase activity both in rats with carbon tetrachloride induced liver damage and in patients with chronic hepatitis and liver cirrhosis. However, it is also known that repeated treatments with high doses of malotilate (at a dose of 250 mg/kg or more) induce anemia in rats (2) and dogs (3) . We often meet with anemias in toxicity tests in which large amounts of a drug have been administered for a long time. Under these circumstances, further hemato logical examinations including the life span of erythrocytes, ferrokinetics, hemorrheology, anti-oxidative factors and membrane in gredients, as well as reversibility of the anemia, are required.
In this report, we report the profile of malotilate-induced hemolytic anemia and lipid metabolism as sociated with the anemia in rats. These profiles are quite different from those reported in many studies describing oxidative hemo lytic anemia.
Materials and Methods

Animals
Six to 8-week-old male SD rats weighing 180-300 g were used. They were maintained on standard laboratory chow and tap water ad libitum in an air-conditioned room (temperature of 23±2'C, relative humidity of 55±10%) for at least one week before use.
Identification of anemic response
Groups of 5 rats each were treated orally for 5 weeks with serial doses of malotilate (62.5-1,000 mg/kg) suspended in sodium carboxymethylcellulose.
During this period, blood samples were collected (4) from each rat at weekly intervals. Blood collection and sacrifice were performed 24 hr after the final dosing. Red blood cell count (RBC), hemat ocrit (Ht), hemoglobin (Hb), mean cor puscular volume (MCV) and reticulocyte count were determined, and morphological observations were made. In addition, serum biochemistry and histochemical examinations of spleen, liver and kidney using Berlin-blue and hematoxylin-eosin staining were per formed at the termination of treatments. Analysis of erythrocyte parameters 1) Scanning electron microscopy (SEM) of erythrocytes: Whole blood obtained from rats treated with 1,000 mg/kg of malotilate for 7 days was fixed with 1 % glutaraldehyde and osmium tetraoxide in 0.1 M phosphate buffer, and then dehydrated through a graded ethanol series. The specimens were critical point-dried, coated with platinum and examined with a Hitachi S-450 scanning electron microscope.
2) Life span of erythrocytes: Six animals each were treated with 100 or 1,000 mg/kg of malotilate for 16 days. Just before the first dosing, erythrocytes were labelled with 20 itCi of Na251 CrO4 (105 mCi/mg Cr, Daiichi Radioisotope) (5), as previously described (6) . The half life of the erythrocyte (t1 /2) and organ accumulation of the radio activity were determined.
3) Ferrokinetics: Pooled rat plasma was labelled with 59Fe-citrate (11.1 mCi/mg Fe: New England Nuclear) for 30 min at room temperature (7) and injected with 11.1 /tCi/ kg before the 5th dosing. Then 150 id blood samples were collected repeatedly from the tail vein and separated into plasma and packed cells. The radioactivity of 50 ail of plasma and of a 40 ,ul suspension of erythrocytes, washed 3 times with normal saline, was counted by the use of an Aloka gamma counter. In the later samples, Hb values were also determined. Using ferrokinetic analysis with these data, plasma iron disappearance (PID) and iron utilized by hemoglobin synthesis (count in blood cells/Hb) were calculated. At the termination of the experiment, the radio activity in the tissues was determined.
4) Rheological and physico-chemical parameters:
Erythrocyte deformability (8), blood viscosity (9) and mechanical hemolysis were determined as previously reported (6) . Briefly, deformability was determined by measuring the speed at which whole blood passed through a membrane filter, and blood viscosity was measured using an E-type rotational viscometer. Mechanical hemolysis was determined by measuring hemoglobin released when whole blood was mixed with normal saline by use of a vortex mixer. Osmotic resistance to hypotonic pressure was examined by measuring hemoglobin concen trations in the supernatants when 20 /d of blood was added to 2 ml of NaCI solutions at serial concentrations (0-0.6%) and stood for at least 30 min at room temperature. Half a milliliter of rat serum obtained 3 hr after a single administration of 1,000 mg/kg malotilate and an equal volume of 0.1 M Tris-HCI buffer (pH 7.4) containing 100 U/ml penicillin and 100 gig/ml streptomycin were preincubated with 0.5 / CI 1,2-3H(N) cholesterol (105 mCi/mg: New England Nuclear) at 37*C for 1 hr (14) . Then 0.5 ml of normal ghosts (0.3-0.5 mg cholesterol) was added to the suspension and incubated for at most 24 hr. Then, the ghost suspension in a 200 zd volume was washed 3 times (16,000xg) with the same buffer, solubilized with 1.5 ml chloroform-methanol and dried in a vial tube. The radioactivity incorporated into ghost membranes was measured using a liquid scintillation counter. In addition, ghosts obtained from rats after the treatment with 1,000 mg/kg malotilate for 5 days was used for the assay of cholesterol incorporation without adding serum. For statistical analysis, Student's t-test was used.
Results
Identification
of anemic response: When rats received malotilate for 5 weeks, RBC, Ht and Hb values decreased, and the re ticulocyte count increased at doses of 500 measured. In rats treated with 1,000 mg/kg malotilate, a marked decrease in erythrocyte survival was seen. The apparent half life was shortened from 15 to 2 days (Fig. 2) . The maximum accumulation of radioactivity in the spleen, liver and kidney was noted in the same group. Ferrokinetics were also deter mined using 59Fe-labelled plasma (Fig. 3) . At a dose of 1,000 mg/kg, plasma iron disappearance (PID) was significantly short ened from 46.5 to 35.8 min.
Maximal incorporation of 59Fe (i.e., iron utilized by hemoglobin synthesis) was attained two days earlier than in the controls at values that were twice those of the controls, whereas the circulating radioactivity rapidly dropped there after. The accumulation of radioactivity in the spleen increased 23-fold of the control value and reached 20% of the total injected. To exclude the re-utilization of 59Fe derived from destroyed hemoglobin, non-radioactive citrate-iron (15 mg/kg) was injected subcu taneously on days 3, 9, 16 and 23. However, the ferrokinetics of these rats treated with or without malotilate were found to be the same as those described above (data not shown).
Thus, shortening of erythrocyte survival and potentiation of iron turnover were recognized in anemic rats treated with malotilate. Fig. 2 . Life span of erythrocytes (left) and 51Cr accumulation in the spleen, liver and kidney (right) in rats treated orally with malotilate for 17 days. The radioactivity at 24 hr following the injection of tagged cells was taken as 100% in the calculation of subsequent survival. ty._, in the left figure means the half life in days of the radioactivity in the circulation.
Organ distribution of the radioactivity was expressed as a percent of total radioactivities injected. Values are the mean±S.E. of six rats. *: P<0.05, **: P<0.01 vs. Control. 
Hemorrheological
examinations were per formed during 3 weeks of treatment. Whole blood viscosity at a shear rate of 76.8 was slightly increased in the high-dose group (Table 3) . Erythrocyte deformability did not show constant changes throughout the treatment.
Furthermore, the resistance of erythrocytes to physico-chemical stimuli was investigated. Although the changes were not significant because of large deviations, ery throcytes from rats in the high-dose group were apt to be less resistant to mechanical stimuli (Table 3) , while osmotic resistance to hypotonic pressure increased at a concen tration of 0.4-0.45% NaCI, which is critical for osmotically induced hemolysis (Fig. 4) .
As shown in Table 4 , G6PD activity and GSH content, anti-oxidative parameters in the erythrocytes, increased in the high-dose group during the study period. In contrast, methemoglobin content determined at weeks 2 and 3 ranged from 1 to 2% of the total hemoglobin in all groups and was not affected by the treatment. Blood cells were obtained from rats treated with 1,000 mg/kg malotilate for 1-3 weeks, and they were added to solutions containing serial concentrations of NaCl. The hemolysis rate (%) was represented as a percent±S.E. of total hemolysis induced by distilled water. *: P<0.05, **: P<0.01 vs. Control. Lipid content of erythrocytes, serum and liver: When rats were treated with 1,000 mg/ kg malotilate for 3 weeks, the lipid content of the erythrocyte membrane and of the serum showed several alterations, as follows. The serum cholesterol level was 58 mg/dl more than the control value at the first week, thereafter showed a slight reduction. This was mainly attributable to an increase in esterified cholesterol (Table 5 ). Since the serum PL level also increased, the FC/PL ratio was significantly higher than that of the control only at week 1. The erythrocyte membrane FC increased at weeks 1 and 2 in the high-dose group, and membrane FC/PL increased significantly at week 3.
In addition, the relationship between time courses of the anemia and lipid alterations in the high-dose group was investigated. As shown in Fig. 5 , RBC values began to fall from day 4, whereas the serum and membrane cholesterol levels were raised from days 4 and 6, respectively.
Negative cooperativity was noted between the RBC and serum TC values (r=-0.785) obtained from repeated sampling through the one-week treatment. Liver EC was also higher than in the controls even on day 3, but the FC value was not altered (Fig. 5) . Figure 6 shows the results from the transmembrane exchange of cholesterol in vitro. More than 5% of added 3H-cholesterol was incorporated into erythrocyte membrane during the 24 hr incubation. When the serum from blood drawn at 3 hr post-medication of 1,000 mg/kg (the peak time of serum malotilate level) was added to the culture, the incorporation of radioactivity was slightly but significantly increased from the thirtieth minute onwards.
On the other hand, the erythrocyte membrane from anemic rats treated with 1,000 mg/kg for 5 days had a low cholesterol uptake capacity, with 20% reduction at 24 hr of incubation.
Discussion
At a repeated dose of 500 mg/kg or more, malotilate induced anemia in rats within the first week. Several parameters such as ery throcyte life span, ferrokinetics, reticulocyte count and hemosiderin deposition related to anemic responses suggested that the con dition was hemolytic anemia associated with elevation of erythrocyte turnover. In a preliminary study, the number of colonies derived from erythroid progenitor (CFU-E) and the serum erythropoietin concentration increased in response to the anemia (data not shown).
Malotilate-induced anemia is also known to occur in dogs but not in mice and monkeys, indicating the presence of species specificity. This may be due to the difference of erythrocyte sensitivity or to that of drug metabolism among the species. In general, the order of potency of erythrocytes in resisting osmotic pressure is: in monkeys> rats>dogs.
Since malotilate caused an increase in osmotic resistance in rats, it is unlikely that the anemia is related to the potency of erythrocyte fragility, and species specificity of the anemia may be attributable to drug metabolism differences. An increase in the content of G6PD and GSH, which play a role in protection of erythrocytes from the oxidative state, has been also seen in the liver as one of the pharmacological effects of malotilate. On the other hand, immature erythrocytes including reticulocytes contain high levels of G6PD and GSH. Therefore, malotilate induced anemia does not seem to be caused by oxidation of erythrocytes.
The enhancement of osmotic resistance, which is also known in malotilate-treated dogs, would indicate a characteristic increase in the surface-to-volume ratio of erythrocytes. A target cell that appeared in the peripheral blood has a normal volume but an increased surface area, which gives them a broad, flat configuration.
Moreover, an increased resistance of target cells to osmotic lysis is also known (15) .
Since malotilate stimulates the synthesis of lipids, in particular synthesis of cholesterol in the liver, and their release into the circu lation (16), the lipid contents of the ery throcyte membrane, serum and liver were measured, and increases in cholesterol and phospholipids were found in all these tissues. In man, several hemolytic anemias associated with changes of membrane lipids are known, for example, spur cell anemia, abetalipopro teinemia (17) and lecitin:cholesterol acyl transferase (LCAT) deficiency (18) . Among these, obstructive jaundice has the most common characteristics to those induced by malotilate with respect to lipid metabolism (15) . In some patients with obstructive jaundice, target cells appear, and osmotic resistance increases. However, erythrocyte survival is only slightly reduced, and bile is retained in the liver, which does not indicate a precise correspondence of lipid metabolism with malotilate-induced anemia. Hypocholesterolemia has been maintained naturally in normal rats-though not in guinea-pigs, rabbits and other species mainly because of the rapid clearance of LDL from the circulation (19) and the lack of the apoprotein D that transfers LCAT-produced These characteristics make it difficult to induce hypercholesterolemia in rats, and even when this is possible, a decrease in membrane PL rather than an increase in membrane cholesterol occurs predominantly under feeding with a cholesterol diet (6) .
In view of the present finding that malotilate increases the level of serum and membrane cholesterol in normal rats, malo tilate may alter lipoprotein metabolism in the plasma as a result of the enhancement of lipid or lipoprotein syntheses in the liver.
In addition, cholesterol incorporation into normal erythrocyte membranes was increased by adding serum from rats treated with malotilate, indicating the possibility that malotilate or its metabolite(s) contained in serum could increase cholesterol incor poration directly or via a change of serum components.
In contrast, cholesterol incor poration into erythrocyte ghosts from anemic rats given malotilate was reduced.
In this case, the cholesterol content of the membrane was 25% higher than that in the controls, and the equilibrium in cholesterol exchanges between membrane and medium seemed to have shifted in the direction of the former. Bloj et al. (21) showed the reduction of cholesterol incorporation into the erythrocyte membrane in rats fed a cholesterol diet and suggested that the cholesterol content did not alter because of potentiation of cholesterol turnover in the membrane.
The subtypes of the increased cholesterol in liver and serum were found to be of the esterified rather than the free form, although free cholesterol generally accounts for the major part of tissue cholesterol.
Thus it is considered that the increase in esterified cholesterol is derived from the LCAT pathway and that the potentiation of LCAT activity occurs in response to an increase in free cholesterol produced and released by the liver. This facilitation of esterification would maintain the cholesterol level in the membrane within the normal range. membrane directly, as well as causing the alteration of lipid content in order to induce rapid and severe anemia.
